semaglutide nash Is the treatment for we've been waiting for? Current and future pharmacological therapies
Description
Both outcomes are normal at the 0.25 mg dose
Where tirzepatide differs from semaglutide is that it also activates another hormone receptor: GIP (glucose-dependent insulinotropic polypeptide)
Studies suggest that sema helps lower both fasting and postprandial glucose levels by improving insulin sensitivity, reducing hepatic glucose output, and delaying gastric emptying, which collectively help flatten glucose spikes after meals
By doing so, it helps reduce blood sugar spikes after meals
8 , e12268 (2022)
